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Low molecular weight PEG-PLGA polymers provide a superior 
matrix for conjugated polymer nanoparticles in terms of 
physicochemical properties, biocompatibility and 
optical/photoacoustic performance  
Thais Fedatto Abelhaa*, Paul Robert Neumannb*, Joost Holthofc, Cécile A. Dreissd, Cameron 
Alexandera, Mark Greene and Lea Ann Daileyb 
The near-infrared absorbing conjugated polymer poly[2,6-(4,4-bis-(2-ethylhexyl)-4H-cyclopenta[2,1-b;3,4-b′]-dithiophene)-
alt-4,7-(2,1,3-benzothiadiazole)] (PCPDTBT) has been investigated as a contrast agent for optical and photoacoustic imaging. 
Lipophilic -conjugated polymers can be efficiently encapsulated within self-assembling diblock copolymer poly (ethylene 
glycol) methyl ether-block-poly (lactide-co-glycolide) (PEG-PLGA) nanoparticles, although the effect of variations in PEG and 
PLGA chain lengths on nanoparticle properties, performance and biocompatbility have not yet been investigated. In this 
study, PEG-PLGA with different block lengths (PEG2kDa-PLGA4kDa, PEG2kDa-PLGA15kDa and PEG5kDa-PLGA55kDa) were used to 
encapsulate PCPDTBT. Nanoparticle sizes were smallest (<100 nm) when using PEG2kDa-PLGA4kDa,with  < 5% PCPDTBT content 
and a reduction in the total solids concentration of the organic phase. All PEG-PLGA nanoparticles were colloidally stable in 
water and serum-supplemented cell culture medium over 24 h at 37°C, with slight evidence of protein surface adsorption. 
PEG2kDa-PLGA4kDa systems showed a threefold lower cytotoxicity (IC50 value) than the other two systems. Haemolytic activity 
was < 2.5% for all systems and no platelet aggregation or inhibition of ADP-induced platelet aggregation was observed. 
Encapsulation of PCPDTBT within a PEG-PGLA matrix shifted fluorescence emission towards red wavelengths (760 nm in THF 
vs 840 nm in nanoparticles) and reduced the quantum yield by 30-70-fold compared to THF. Nonetheless, PCPDTBT: PEG2kDa-
PLGA4kDa systems had a marginally higher quantum yield and signal-to-background ratio in a phantom mouse compared with 
PEG2kDa-PLGA15kDa and PEG5kDa-PLGA55kDa systems. As a photoacoustic imaging probe, PCPDTBT: PEG2kDa-PLGA4kDa systems also 
showed a higher photoacoustic amplitude compared to higher molecular weight PEG-PLGA systems. Overall, the low 
molecular weight PEG2kDa-PLGA4kDa nanoparticle systems conferred the benefits of smaller sizes, reduced cytotoxicity and 
enhanced imaging performance compared to higher molecular weight matrix polymers.
Introduction 
Bioimaging is used in research to understand physiological 
and pathological processes and it plays a crucial role in the 
diagnosis and monitoring of the progress of disease 1. Given its 
importance, there is an increasing demand for biocompatible 
imaging agents with improved performance that would benefit 
researchers, patients and medical doctors. Among the different 
materials explored for the acquisition of images, conjugated 
polymer nanoparticles (CPNs) are attractive candidates for 
cellular labelling or biomedical imaging and have emerged as an 
alternative to quantum dots and small molecule dyes, because 
they show higher brightness, increased photostability and 
negligible cytotoxicity 2,3. 
The conjugated polymer, poly[2,6-(4,4-bis-(2-ethylhexyl)-
4H-cyclopenta[2,1-b;3,4-b′]-dithiophene)-alt-4,7-(2,1,3-
benzothiadiazole)] (PCPDTBT, Figure 1), was first synthesised in 
2006 as a promising new low-bandgap material (i.e. requiring a 
lower amount of energy absorption to conduct 4) for organic 
photovoltaic applications 5. PCPDTBT is composed of alternating 
units of electron-rich cyclopentadithiophene (CPDT) and 
electron-poor benzothiadiazole (BT), showing maximum 
absorbance and emission in the near infra-red 5,6 (Figure 1). 
While the broad absorbance of PCPDTBT within the terrestrial 
solar spectrum has attracted attention for improved 
performance of organic solar cells 6–9, its near-infrared 
absorbance/emission and photoacoustic properties is 
promising for biomedical imaging applications 10–15 and 
photothermal ablation 11,12,16–18.  
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Figure 1: Chemical structure, absorption and emission spectra 
of PCPDTBT in tetrahydrofuran (THF). 
 
As a highly lipophilic polymer, PCPDTBT is typically 
embedded in nanoparticle-based structures with varying 
chemical composition and characteristics 6–14. Several studies 
report using nanoprecipitation or mini-emulsion methods to 
produce CPNs with a PCPDTBT core covered by an adsorbed 
layer of phospholipid surfactants 10,12,16,19,20, such as 1,2-
dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) 10,20. Triblock 
copolymers of PEG and poly-(propylene glycol) (PEG-b-PPG-b-
PEG) have also been used 11, as well as strategies that embed 
the conjugated polymer within silica creating multi-layer 
nanoparticle architectures 13,14,21. The disadvantage of core-
shell CPNs is the observation that many types of amphiphilic 
stabilising agents, such as phospholipids, are displaced from the 
particle surface in biological fluids 22. Nonetheless, 
PCPDTBT/DPPC CPNs have shown strong and stable 
photoacoustic (PA) signals, enabling whole-body lymph-node 
mapping in living mice at low mass concentration10, while PA 
imaging and photothermal ablation of tumours in living mice 
was achieved with nanoparticles of PCPDTBT doped with (6,6)-
phenyl-C71-butyric acid methyl ester (PC70BM) prepared with 
PEG-b-PPG-b-PEG 11. 
The biodegradable copolymer, poly (ethylene glycol) methyl 
ether-block-poly (lactide-co-glycolide) (PEG-PLGA), has been 
extensively investigated for drug delivery applications due to its 
excellent degradation and biocompatibility 23,24. Additionally, 
PEG-PLGA has been successfully used as a encapsulating agent 
for conjugated polymers 25,26. The lipophilic PLGA chains self-
assemble in aqueous solutions to form a hydrophobic matrix 
which can effectively incorporate lipophilic compounds, whilst 
the PEG component of the diblock copolymer provides steric 
stabilisation through orientation of the hydrophilic PEG chains 
on the surface of the nanoparticles. This stable PEG coating 
improves colloidal stability and reduces interactions with blood 
components, an effect referred to as a stealth behaviour 27. Due 
to the self-assembling characteristics of the amphiphilic PEG-
PLGA copolymer, nanoparticles can be prepared through 
nanoprecipitation, a simple and low energy input process with 
a high product yield 28,29. 
Nanoparticles engineered for biomedical imaging 
applications should perform their designated function without 
harming tissues and cells that are exposed to them 30,31. A pre-
clinical evaluation of nanoparticle interactions with cells is 
usually the first step to evaluate the risk-benefit ratio of a new 
material 30. Preliminary biocompatibility assays include the in 
vitro examination of the interaction of nanoparticles with 
relevant biological components such as those present in blood 
30,31. While many reports of CPNs prepared for bioimaging 
applications have included cytotoxicity assessment in different 
cell lines 14,17,20–22,26,32, the study of the compatibility of CPNs 
with relevant blood components is less common in the 
literature 33. Additionally, many studies that have shown the 
potential of CPNs as bioimaging agents did not include any 
biocompatibility assessment 34–39. While the physicochemical 
characterisation of CPNs is vital to rationalise the design of 
imaging agents, a preliminary safety assessment is a key step 
towards their commercial and clinical applicability.  
In this work, PEG-PLGA of different block lengths (PEG2kDa-
PLGA4kDa, PEG2kDa-PLGA15kDa and PEG5kDa-PLGA55kDa) were 
investigated as nanocarriers of PCPDTBT. The impact of the 
different PEG-PLGA compositions on nanoparticle 
physicochemical properties, biocompatibility and imaging 
performance was investigated. It was hypothesised that 
increasing PLGA molecular weight in the diblock copolymer may 
lead to an increase in nanoparticle size but could also 
concurrently show a favourable effect on PCPDTBT optical 
properties, due to an increase in the hydrophobic environment 
of the embedded conjugated polymer. It was further 




PCPDTBT (cat # 754005) with an average molecular weight 
of 7482 Da and the three different types of PEG-PLGA 
copolymers with 50:50 ratio of lactide/glycolide (PEG2kDa-
PLGA4kDa, PEG2kDa-PLGA15kDa and PEG5kDa-PLGA55kDa) were 
purchased from Sigma-Aldrich Corporation (St Louis, MO, USA), 
in addition to the following reagents: THF (ReagentPlus®, 
≥99.0%,); heat inactivated FBS; purified HPLC water (impurities 
≤1ppb and anions ≤ 0.1 mg/kg); NaCl, MTT (3-(4,5-
dimethylthazol-2-yl)-2,5-diphenyl tetrazolium bromide), 
haemoglobin standard (human), Dulbecco’s phosphate 
buffered saline Ca2+/Mg2+ free (DPBS), cyanmethemoglobin 
(CMH) reagent (Drabkin’s reagent), adenosine 5′-diphosphate 
sodium salt (ADP), Triton® X-100 (4-(1,1,3,3-Tetramethylbutyl) 
phenyl-polyethylene glycol, t-octylphenoxypolyethoxyethanol, 
polyethylene glycol tert-octylphenyl ether) and trypan blue 
solution. High glucose phenol red free DMEM cell culture 
medium (CCM); pen strep (10,000 units of penicillin and 10 mg 
streptomycin/mL); L-glutamine 200 mM; HEPES buffer 1M and 
pyruvate 100 mM were obtained from Gibco® (Life 
TechnologiesTM, Paisley, UK). Dimethyl formamide (DMF, 50% 
solution) was acquired from Severn Biotech Ltd (Kidderminster, 
UK). Phosphate buffered saline (PBS) (“Dulbecco A” tablets) was 
acquired from Oxoid Ltd (England). The BALB/C monocyte-
macrophage J774A.1 cell line (TIB-67TM, LOT:60880169) was 
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acquired from American Type Culture Collection (ATCC®, 
Virginia, USA). Chemicals were used as received without further 
purification. 
 
Preparation of nanoparticles 
PCPDTBT CPNs were prepared by nanoprecipitation 25,26. 
Briefly, 1 mL of PCPDTBT + PEG-PLGA solution in THF was added 
dropwise to 5 mL of water at room temperature stirred for up 
to 12 hours to allow complete evaporation of the solvent. The 
volume of water lost due to evaporation was replaced. 
Corresponding formulations containing 100% PEG-PLGA were 
prepared as controls. At least three independent replicate 
batches of each formulation were produced and characterised. 
All nanoparticle batches were characterized without filtration 
or purification. An optimisation study was performed with the 
three PEG-PLGA structures to assess the effect of PCPDTBT 
content (0-50% w/w) and total solids concentration (0.2-2.1 
mg/mL) on CPN properties.  
 
Dynamic light scattering (DLS) and zeta potential: 
Hydrodynamic diameters (HD) were assessed by DLS using a 
Zetasizer NanoZS (Malvern Instruments Ltd, UK) equipped with 
a 633 nm He-Ne laser and a backscatter detector with a 
measurement angle of 173°. The size analysis was performed at 
25°C (0.8872 cP) at 50 µg/mL total solids concentration. The Z-
average value obtained from the intensity distribution of 
particles size was expressed as a mean diameter for 
distributions which were found to be monomodal. The zeta 
potential was measured at 25°C after sample dilution in NaCl 10 
mM 40,41 to a final polymer concentration of 20 µg/mL in 
standard electrophoresis cuvettes (DTS1070, Malvern 
Instruments GmbH) in a Zetasizer NanoZS (Malvern Instruments 
Ltd, UK). 
 
Scanning electron microscopy (SEM): Nanoparticles comprised 
of PEG2kDa-PLGA15kDa or PEG5kDa-PLGA55kDa containing 0 or 5% 
PCPDTBT (2.1 or 2.0 mg/mL total solids concentration) were 
assessed by SEM on a Hitachi S-4000 (Tokyo, Japan) at 25 kV and 
at 0/45°-tilt by air drying 50 µL of nanoparticle solution on a 
cover slip followed by coating with 15 nm of gold. From SEM 
images, the nanoparticle size distribution was determined using 
ImageJ software 42. 
 
Nanoparticle stability in physiological media 
The pH, size, and zeta potential of containing 0 or 5% PCPDTBT 
prepared at 2.1 mg/mL total solids concentration was measured 
before and after 24-hour incubation period at 37°C in water and 
CCM (DMEM supplemented with 10% FBS, 1% antibiotics, 1% L-
glutamine 200mM, 1% HEPES buffer 1M and 1% pyruvate 100 
mM) at final nanoparticle concentration of 300 µg/mL. 
Nanoparticle tracking analysis (NTA; Malvern Instruments Ltd, 
UK) was used to assess hydrodynamic diameter in this study 
component. Following incubation, the formulations were 
diluted to 10.5 μg/ml with filtered (0.22 μm CA filter) bidistilled 
water before NTA measurement (532nm laser unit). Data is 
shown in Figure S1, ESI. 
 
MTT cytotoxicity assay: The J774A.1 cell line (referred to J77A for 
simplicity) was mycoplasma free, tested by the Hoechst stain 
(Bisbenzimide H 33258) method 43. J774 cells were cultured in DMEM 
supplemented with 10% FBS, 1% antibiotics (100 U penicillin and 0.1 
mg/ml streptomycin), 1% sodium pyruvate (100 mM) and 5% L-
glutamine (200 mM). For the MTT assay, 60 inner wells of a 96-well 
plate were seeded with 25,000 cells/well 44 and the tetrazolium salt 
MTT colorimetric assay was used to assess the J774 cell line survival 
following incubation at 37°C for 24 h with nanoparticle suspensions 
(200 µL; nanoparticle concentration 0.1-300 µg/mL) in CCM. To 
control for effects of hypotonicity, CCM was diluted in the following 
ratios 1:4, 1:12 and 1:32 H2O:CCM with sterile water and also 
incubated with the cells (Figure S4). Negative controls consisted of 
cells incubated with fresh CCM for 24 h and positive controls 
consisted of cells exposed to fresh CCM for 24 h followed by a 10 min 
incubation 100 µL of Triton-X 1% solution. Following incubation, cells 
were washed twice with 200 µL of warm PBS, then incubated for 4 h 
at 37°C with MTT solution (1 mg/mL 45) followed by the addition of 
100 µL of 10% SDS and 50% DMF solution 45 and incubation for 24 h 
at 37°C to solubilize the formazan crystals. Subsequently, the 
absorbance was measured at λ = 570 nm (formazan) in a plate reader 
(Spectramax 340 PC384). At 570 nm, the tested CPNs presented 
absorbance lower than 0.1 at 7 µg/mL PCPDTBT (conjugated polymer 
content in 150 µg/mL nanoparticle solution) and it was assumed that 
any residual CPN would not be at sufficient concentration to 
interfere with the formazan measurement. Cytotoxicity assays were 
repeated for a minimum of three times with different passage 
numbers, in accordance to the ISO 10993-5 (tests for in vitro 
cytotoxicity) 46. To negate the effects of different sedimentation and 
diffusion velocities on the dose of nanoparticles reaching the cell 
layer, the cell viability results were plotted against the delivered dose 
(µg/cm2) rather than the administered dose (µg/mL) 47. The delivered 
dose values were calculated with the In Vitro Sedimentation,  
Diffusion and Dosimetry (ISDD) model 48, using the NTA-derived 
hydrodynamic diameters measured after 24 h in CCM as input values. 
 
Haemocompatibility 
The assessment of the nanoparticle interactions with 
relevant blood components involved the collection of blood 
from healthy volunteers, which provided consent, and the 
project was approved by the institutional Ethics Committee 
(reference 10/H0807/99).  
 
Haemolysis: The haemolysis assay was based on a colorimetric 
detection of red-coloured cyanmethemoglobin (CMH) 49,33,50,51. 
Duplicate samples of 100 µL of nanoparticle dispersions (300, 30, 3 
µg/mL), water (the nanoparticle vehicle), DPBS (negative control) 
and Triton X-100 1% (positive control) were added to 
microcentrifuge tubes and incubated 3 h (± 15 min) at 37°C, with 100 
µL of blood standardized to a haemoglobin concentration of 10 ± 2 
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mg/mL, with gentle mixing every 30 minutes. Samples were then 
centrifuged 15 minutes at 800 g and 100 µL supernatant was added 
to a 96-well plate containing 100 µL of CMH. The absorbance of the 
plate was read at 540 nm in a plate reader Spectramax 340 PC384 
(Program Softmax pro 6.2.2) and haemoglobin concentrations were 
determined from a haemoglobin calibration curve. PCPDTBT content 
was accounted for by subtracting the background absorbance of 
samples containing nanoparticles, but no blood. 
 
Platelet aggregation: The assessment of platelet aggregation was 
based light transmission aggregometry in a 96-well plate 52. Briefly, 
platelet rich plasma (PRP) and platelet poor plasma (PPP) were 
isolated from whole human blood and 100 µL added to a 96 well 
plate. Nanoparticle dispersions were prepared in water so that when 
10 µL were added to PRP/PPP samples a concentration of 300, 30, 3 
µg/mL was achieved. Subsequently, samples were received either 10 
µL ADP (12 mM in PBS) to induce platelet aggregation or 10 µL PBS 
only. Controls consisted of 100 µL PRP (0% aggregation) and 100 µL 
PRP containing 10 µL of ADP stock solution (100% aggregation), while 
PPP containing nanoparticles at different concentrations were used 
to subtract the background. To account for the plasma dilution by 
nanoparticle samples, 10 µL water was added to the controls and 
blank and PBS was used to complete the volume of samples to reach 
a standardized final volume of 120 µL. The transmittance was 
measured immediately following ADP addition at 595 nm 
(Spectramax 340 PC384). The analysis was performed at 37°C with a 
total read time of 16 minutes with interval measurements every 15 
seconds and 7 seconds plate shaking before each read. In all the 
experiments, the number of platelets in PRP were within the normal 
range of 1.89-3.99x108 cells/mL 52. 
 
Absorbance and emission spectra: Spectra of PCPDTBT 
dissolved in THF and nanoparticles diluted in water to 1.7 µg/mL 
PDPCTBT were measured with a wavelength-calibrated 
FluoroMax-4 spectrofluorometer (Horiba Jobin Yvon). The 
absorption spectra were acquired following 860 nm emission; 
emission spectra were acquired following 550 nm excitation. 
For both, absorption and emission spectra the 
excitation/emission slit was set to 1 nm and the integration time 
to 0.5 seconds.  
 
Quantum yield: QY values were measured with the Fluoromax 
4 using the PTI K-Sphere in the sample compartment. A 10 mm 
quartz cuvette was used. To avoid inner-filter effects from 
reabsorption, the sample was diluted that the absorbance at 
the excitation wavelength was less than 0.1. In order not to 
oversaturate the photomultiplier detector (PMT), the signal 
strength was checked in the real time control (RTC). Neutral-
density filter (ND) were used on the excitation side to reduce 
the intensity on the Rayleigh scatter to stay within linear range 
of the detector (1 million to 1.5 million CPS on the raw S1 signal). 
Slits on the excitation and emission monochromators were set 
to 3 nm in the sample measurement. Integration time was set 
to 1 s. The area balance factor (ABF) needed for the QY tool was 
assessed by measuring the spectrum in question once with and 
without the required filter combination. The ABF is the quotient 
of the integrated curves of the relevant spectra. 
 
Optical imaging performance in a phantom mouse: CPNs and 
Indocyanine green (ICG) were diluted in deionised water to give 
equivalent fluorophore masses of 0.125, 0.25. 0.5 and 1 µg per 
10 µL. A further sample of ICG diluted in human serum albumin 
solution (40 mg/mL) was also prepared to mimic the effect of in 
vivo protein binding on ICG fluorescence 53,54. A 10 µL volume of 
each sample was pipetted into a narrow silicon tube and 
positioned in one of two available bores in an XFM-2 phantom 
mouse (PerkinElmer/Caliper). The bores were located at 4.0 
mm (ventral position) and 17.0 mm (dorsal position) distance 
from the imaging surface. Images were acquired using the 
epifluorescence mode of the IVIS Spectrum 
(PerkinElmer/Caliper). Samples within the mouse contained 
0.125, 0.25, 0.5 and 1 µg fluorophore and images were acquired 
using the following excitation and emission wavelengths:  λex= 
745 nm, λem= 820 nm (ICG) and λex= 745 nm, λem= 840 nm 
(PCPDTBT). For all experiments an identical region of interest 
(ROI) was used to evaluation total radiant efficiency. From this, 
a signal-to-background ratio (SBR) was calculated for each 
wavelength combination using the phantom mouse without 
sample inside as a background reference. All quantitative 
measurements of fluorescence signal were performed utilizing 
the Living Image v. 4.3.1 software (PerkinElmer/Caliper).  
 
PA imaging performance in a phantom: PA measurements were 
carried out by using the Vevo-LAZR X (FUJIFILM Visualsonics, The 
Netherlands). Vevo LAZR-X is a multimodal platform which allows the 
simultaneous imaging of high-resolution ultrasound and 
photoacoustics. The system was equipped with a linear array of 
ultrasound transducer at a central frequency 21 MHz (MX 250) and 2 
fiber optic bundles on either side of the transducer for the 
illumination. The fiber bundle was coupled to a tunable Nd: YAG laser 
(680 to 970 nm) with a 20 Hz repetition rate. A commercially 
available phantom (Vevo Phantom, VisualSonics, Amsterdam) which 
consisted of transparent capillary tubes was used for the sample 
characterisation. The tubes were mounted on an acrylic dish filled 
with distilled water for better coupling of the generated sound 
signals. Different contrast agent masses (6.25-100 µg) were injected 
into the capillary tubing and the system acquired a sequence of PA 
images in the wavelength range of 680-970 nm with a step size of 5 
nm in the spectral mode. After acquisition, images were analysed 
using Vevo LAB software (FUJIFILM Visualsonics, The Netherlands) 
and the spectral characteristics of the samples were recorded. 3-
dimensional spectral imaging of the tubes was also performed using 
a 2D stepper-motor and linear translation of the transducer over the 
capillary tubes. Experiments were performed in triplicate. 
Statistical analysis 
The multivariate analysis of particle size determinants was 
performed with Excel 2013 (Microsoft, Inc). GraphPad Prism 
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(version 5.00 for Windows, GraphPad Software, San Diego 
California, USA) was used to perform all other statistical 
analyses (One-way ANOVA with Tukey post hoc test and 
regression analysis). Statistical significance values were 
described as * p≤0.05 ** p≤0.01, *** p≤0.001. 
Results and discussion 
Effect of PCPTDTBT content, total solids concentration and PEG-
PLGA structure on CPN size  
A multivariate analysis was performed to evaluate the effect 
of PCPDTBT content, total solids concentration and PEG-PLGA 
block composition (PEG2kDa-PLGA4kDa, PEG2kDa-PLGA15kDa and 
PEG5kDa-PLGA55kDa) on the hydrodynamic diameters of CPNs. A 
minimum of eight formulations with varying PCPDTBT content 
(0-60%) and total solids concentration (0.1-2.4 mg/mL) were 
prepared for each PEG-PLGA grade and multivariate analysis 
was used to generate models predicting the influence of 
PCPDTBT content (x) and total solids concentration (y) on CPN 
hydrodynamic diameter (z; Figure 2). Regression analysis 
showed a moderate to good fit of the data (R2=0.5600-0.9067) 
to the respective models generated for each of the three PEG-
PLGA classes. The models indicated that systems composed of 
the two larger PEG-PLGA polymers, PEG2kDa-PLGA15kDa and 
PEG5kDa-PLGA55kDa, were sensitive to changes in both the 
PCPDTBT content and total solids concentration, whereas the 
particle sizes of systems made from PEG2kDa-PLGA4kDa were 
dependent only on PCPDTBT content. In general, both a 
reduction of the PCPDTBT content and total solids 
concentration led to a reduction in particle size with all three 
PEG-PLGA structures. 
Despite the generally larger particle sizes obtained with 
2.1 mg/mL total solids concentration, the higher particle 
concentration in these formulations facilitated subsequent 
characterisation and cytotoxicity studies and therefore this 
condition was carried forward combined with a low loading 
dose of 5% PCPDTBT. SEM micrographs of PEG2kDa-PLGA15kDa 
and PEG5kDa-PLGA55kDa systems prepared under these conditions 
(Figure 3A/B) showed spherical nanoparticles with median 
diameters smaller than 30 nm and a relatively high dispersity 
(Figure 3C/D). Although the hydrodynamic diameter of 
nanoparticles is typically larger than size measurements 
obtained under dry conditions 55,565, DLS data suggested a low 
polydispersity (<0.17), in contrast to the broad range of sizes 
shown by the SEM images.  
The disparities in size in between the two techniques can 
be explained by the DLS measurements underestimating the 
detection of small nanoparticle populations, due to their lower 
light scattering. This observed DLS limitation has been 
previously reported 55,57. Although the CPNs presented a broad 
size distribution, the observed size range was lower than 
previously described for PLGA nanoparticles (100-550 nm) also 
prepared by nanoprecipitation with PVA surfactant 58. It is 
relevant to mention that most reports found in the literature 
used DLS to assess the size of PEG-PLGA nanoparticles and the 
majority of them did not show TEM or SEM images of 
nanoparticles produced 59–62 or did not estimate their size 
distribution from SEM/TEM images 11,63. The results emphasize 
the importance of using multiple measurement techniques to 
characterise nanoparticle size and distribution. 
Figure 2: Effect of PCPDTBT content (% w/w; x) and total solids 
concentration (mg/mL; y) on nanoparticle hydrodynamic 
diameters (z) for systems produced from PEG2kDa-PLGA4kDa (A), 
PEG2kDa-PLGA15kDa (B), and PEG5kDa-PLGA55kDa (C). Models were 
generated from the mean hydrodynamic diameters of n=3 
different batches prepared under different processing 
conditions (8-14 variations per model). 
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Figure 3: SEM micrographs of PEG5kDa-PLGA55kDa (A) and PEG2kDa-
PLGA15kDa (B) CPNs containing 5% PCPDTBT (2.1 mg/mL total solids). 
The scale bar represents 750 nm. The size distributions of both 
systems were determined by ImageJ analysis (C and D, respectively). 
 
Cytotoxicity 
The MTT-based cytotoxicity technique is a rapid colorimetric 
assay broadly used for nanoparticle safety assessment 59. According 
to ISO 10993-5, materials designed for biomedical applications that 
show cell viability above 80% are classified as having slight 
cytotoxicity, above 50% mild cytotoxicity and below 50% moderate 
toxicity, with the extremes of ~100% and ~0% being categorised as 
non-cytotoxic and severely cytotoxic, respectively 46. Only the 
highest concentrations tested in this study reached values of 40-50% 
viability, i.e. moderate cytotoxicity, making the prediction of full 
dose-response curve slightly less reliable (R2 values of curve fits 
ranged from 0.54-0.88) (Figure 4). 
Nonetheless, differences between the systems were observed, 
for example, increasing PEG-PLGA molecular weight resulted in a 
greater cytotoxicity. Also, systems containing 5% PCPDTBT were 
marginally more cytotoxic than systems without the conjugated 
polymer. Since different hydrodynamic diameters were measured 
for each system, the ISDD model was used to calculate the delivered 
dose (µg/cm2), i.e. the nanoparticle mass to reach the cell layer, 
taking sedimentation and diffusion behaviour of the particles into 
account 47,48. This metric shows that differences in particle size are 
not responsible for the different cytotoxicity profiles seen here. Thus, 
it may be postulated that different PEG densities on the particle 
surface or perhaps different intracellular degradation kinetics may 
be responsible for the different cytotoxicity profiles. Both 





Figure 4: Comparison of the cytotoxicity of (A) PEG2kDa-PLGA4kDa, (B) 
PEG2kDa-PLGA15kDa and C) PEG5kDa-PLGA55kDa containing 0 and 5% 
PCPDTBT in a J774 macrophage-like in vitro model. Cell viability was 
plotted against the ISDD-calculated delivered dose (µg/cm2) to 
negate the effects of different particle sizes on the sedimentation 
and diffusion behaviour of the particles. Values represent the mean 




The percent haemolysis induced by a test sample can be 
classified as non-haemolytic if lower than 2%, slightly haemolytic 
within 2-5% and haemolytic if higher than 5% 50,64,65. Independent of 
the grade of PEG-PLGA and the presence of PCPDTBT, all 
nanoparticles were non-haemolytic at the concentrations tested, 
except for PEG2kDa-PLGA15kDa containing 5% PCPDTBT, which 
presented a slight haemolytic activity (2.3 ± 1.5%) at 300 µg/mL 
(Figure S2A, ESI). As a comparison, CPNs coated with a pegylated 
phosphatidyl-ethanolamine (PE-PEG2kDa) surface stabiliser had 
haemolysis values higher than 10-20% 33, indicating that excess free 
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or displaced surfactant is associated with higher than acceptable 
haemolysis values. Therefore, embedding conjugated polymers into 
PEG-PLGA nanoparticles is an advantageous formulation strategy to 
reduce haemolytic activity 33. 
Nanoparticles intended for intravenous administration should 
ideally be inert to platelets to avoid both pronounced thrombosis 
and anti-thrombotic activity. For example, carbon-based 
nanoparticles have been reported to induce platelet aggregation and 
cause increased vascular thrombosis in rats 66. In the current study, 
no induction of platelet aggregation was observed for all PEG-PLGA 
systems (Figure S2B, ESI). Neither did any system inhibit ADP-
induced aggregation over a 16-minute test period (Figure S2C, ESI). 
This contrasts again with results reported by Khanbeigi, Hashim et al 
2015 33 who observed that PPE:PE-PEG2kDa core-shell CPNs inhibited 
ADP-induced platelet aggregation in a dose-dependent manner. 
Surprisingly, similar CPNs containing PPV in the core did not show 
this effect  33. 
 
Effect of PEG-PLGA structure on CPN optical and PA imaging 
performance  
CPNs prepared with 5% PCPDTBT (2.1 mg/mL total solids) 
showed a slight blue shift in maximum absorbance compared to 
PCPDTBT dissolved in THF (~650 nm vs. ~690 nm, respectively), 
resulting from a decreased conjugation length due to the polymer 
bending in the particle core 67,68 (Figure 5A). The CPNs also exhibited 
a large red-shift in the emission spectra (ʎmax.= 850 nm) in 
comparison to PCPDTBT in THF (ʎmax.= 760 nm), caused by inter-chain 
species originating from increased chain interactions 35,38,56,67,69. A 
red-shift similar magnitude has been previously reported for 
PCPDTBT nanoparticles coated with the phospholipid, DOPC, as 
compared to the conjugated polymer dissolved in chloroform 16. 
Photoluminescence quantum yield values (PLQY%) of the CPNs were 
30-100-fold lower than PCPDTBT in THF (Figure 5B). In spite of a 
similar red shift in their emission spectra, PLQY measurements of 
nanoparticles showed that the block copolymer influenced the 
optical properties of PCPDTBT, with CPNs of PEG2kDa-PLGA4kDa 
presenting the highest PLQY.  
An IVIS Spectrum optical imaging instrument (Perkin-Elmer) was 
employed to characterise the optical performance of the systems in 
a phantom mouse with similar autofluorescence and light scattering 
properties to murine muscle tissue 70. Calculation of the signal to 
background ratios of the different fluorophores enabled 
comparisons between the PCPDTBT nanoparticles and the clinically 
approved NIR fluorophore, ICG (in water and an albumin solution 
representing serum), which has different excitation and emission 
characteristics (Figure 6). Despite the low quantum yield values of 
the CPNs compared to ICG, all three CPN systems showed a 
measurable signal:background ratio (SBR) in a phantom mouse 
model at concentrations > 250 ng, with a nearly linear increase in SBR 
up to 1 µg. As suggested by the slightly higher PLQY% value, the 
PEG2kDa-PLGA4kDa (5% PCPDTBT) consistently outperformed the two 
other PEG-PLGA formulations.  
 
Figure 5: Normalised absorption and emission spectra of PCPDTBT in 
THF and 5% PCPDTBT:PEG-PLGA CPNs dispersed in water (A) and 
photoluminescence quantum yields of systems investigated (B). 
Values represented mean ± standard deviation of n=3 batches. 
 
Resulting from a large molar extinction coefficient of 
approximately ε = 5x107 cm-1M-1, strong thermalisation efficiency 
and consequently strong PA signal generation, PCPDTBT has 
primarily been investigated as a new contrast agent for PA imaging 
10,11,15. Consequently, it was of interest to assess whether the type of 
PEG-PLGA matrix polymer influenced the PA signal of PCPDTBT. 
Normalised PA amplitudes were measured at wavelengths ranging 
from 650 – 1000 nm with PCPDTBT systems showing a maximum at 
~710 nm and ICG in water at ~825 nm (Figure 7A). Maximum PA 
amplitudes at increasing contrast agent masses (6.25-100 µg) were 
then determined in a phantom. The structure of PEG-PLGA had a 
noticeable influence on the maximal PA amplitude, with PEG2kDa-
PLGA4kDa systems showing a much steeper increase in signal with 
increasing dose compared with the other two PEG-PLGA systems 
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(Figure 7B). At the highest mass, the PA amplitude decreased for 
PEG2kDa-PLGA4kDa, to levels comparable to the other two systems. It 
should be noted that the signal variability also increased substantially 
at 100 µg, indicating that the results from this amount of contrast 
agent were less reliable. In comparison to PCPDTBT, the ICG sample 
in water increased exponentially from 6.25-25 µg above which, the 
PA amplitude remained the same. 
 
 
Figure 6: Optical performance of 5% PCPDTBT in three different 
PEG-PLGA nanoparticle systems in a phantom mouse. A) 
Representative images of the control, 0.125 – 1 μg ICG in a 
human serum albumin solution (40 mg/mL), compared with 
0.125 – 1 μg PCPDTBT encapsulated in PEG2kDa-PLGA15kDa. SBR 
ratios for dye mass values of 0.125, 0.25, 0.5 and 1 μg were 
calculated from whole body imaging of a phantom mouse from 
the B) ventral (4 mm penetration depth) and C) dorsal (17 mm 
penetration depth) sides. Values depicted are from a single 
nanoparticle batch. 
 
Figure 7: Normalised PA amplitude spectra (A) and dose-dependency 
of maximal PA amplitude values (B) of 5% PCPDTBT:PEG-PLGA CPNs 
dispersed in water compared with an aqueous ICG solution. Values 
represent the mean ± SD of n=3 experiments from a single batch.  
To our knowledge, this study represents the first report of a 
nanoparticle matrix material influencing the optical and PA 
performance of a conjugated polymer. Throughout the study, the 
PEG2kDa-PLGA4kDa CPNs showed a slight, but consistently better 
performance with regard to physicochemical properties, 
biocompatibility, optical and PA imaging performance than the 
higher molar mass analogues. The reasons for this are not fully clear, 
although it may be postulated that the low molecular weight, more 
hydrophilic PEG2kDa-PLGA4kDa is able to diffuse more rapidly into the 
aqueous medium during the nanoprecipitation event leading to 
formation of a nanoparticle core enriched in PCPDTBT and coated 
with a layer of PEG2kDa-PLGA4kDa at the particle surface. In contrast, 
the larger, more slowly diffusing PEG-PLGA analogues may show a 
higher degree of co-precipitation in the nanoparticle core. The 
presence of PEG-PLGA in the nanoparticle core might enable a higher 
degree of water penetration into the core 75 as compared to a 
putative PCPDTBT-enriched core structure. Water penetration in the 
nanoparticle core could result in the larger hydrodynamic diameters, 
photoluminescence quenching without a shift in the emission 
maximum, as well as changes in conversion efficiency from light 
absorption to ultrasound emission leading to reduced PA amplitudes 
again without an accompanying shift in the PA amplitude spectrum, 
Journal Name  ARTICLE 
This journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 9  
Please do not adjust margins 
Please do not adjust margins 
all effects which were observed in this study. Techniques such as 
small angle neutron scattering would be suitable to investigate this 
hypothesis and could be the focus of future studies. 
Conclusions 
The self-assembling diblock copolymer, PEG-PLGA, has been 
shown to improve CPN characteristics, irrespective of 
conjugated polymer chemistry 25,26. The advantages of PEG-
PLGA as a matrix forming agent for conjugated polymer 
encapsulation include small particle sizes, circumvention of the 
use of adsorbed surfactant to ensure colloidal stability and thus 
no surfactant-related toxicity. PEG-PLGA CPN systems show 
excellent stability in biofluids, a high cytocompatibility, 
excellent haemocompatibility, and promising optical 
performance. To date, the impact of PEG-PLGA structure on 
CPN properties had not been assessed. The current study 
demonstrated that the use of a PEG-PLGA with a relative short 
PLGA block (i.e. PLGA4kDa) with a 2 kDa PEG group conferred 
benefits compared to PEG-PLGAs with longer PLGA chains. 
Overall, the. PEG2kDa-PLGA4kDa systems were smaller in size, had 
a reduced cytotoxicity and a slightly enhanced optical 
performance compared to CPNs produced with PEG2kDa-
PLGA15kDa and PEG5kDa-PLGA55kDa.  
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